Greater response with GSK’s Benlysta vs placebo in SLE study
Data from GSK’s BLISS-SC Phase III study show that patients with highly active systemic lupus erythematosus (SLE) experienced a significantly greater response to treatment with Benlysta (belimumab) 200mg administered via subcutaneous injection plus standard of care (SoC), compared to placebo plus SoC.
Click on this link for more information.
